{"blog": [], "keywords": [{"value": "Valeant Pharmaceuticals International Inc", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Executive Compensation", "name": "subject", "rank": "2", "is_major": "Y"}, {"value": "ValueAct Capital Partners", "name": "organizations", "rank": "3", "is_major": "Y"}, {"value": "Ubben, Jeffrey W", "name": "persons", "rank": "4", "is_major": "N"}, {"value": "Pearson, John Michael (1959- )", "name": "persons", "rank": "5", "is_major": "N"}, {"value": "Ackman, William A", "name": "persons", "rank": "6", "is_major": "N"}, {"value": "Accounting and Accountants", "name": "subject", "rank": "7", "is_major": "N"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "8", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/03/29/business/dealbook/valueact-pays-a-price-for-its-supporting-role-at-valeant.html", "document_type": "article", "byline": {"person": [{"middlename": "Ross", "firstname": "Andrew", "role": "reported", "rank": 1, "lastname": "SORKIN", "organization": ""}], "original": "By ANDREW ROSS SORKIN"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/03/29/business/29dbsorkin-sub/29dbsorkin-sub-thumbWide-v2.jpg", "legacy": {"wide": "images/2016/03/29/business/29dbsorkin-sub/29dbsorkin-sub-thumbWide-v2.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/03/29/business/29dbsorkin-sub/29dbsorkin-sub-articleLarge.jpg", "legacy": {"xlarge": "images/2016/03/29/business/29dbsorkin-sub/29dbsorkin-sub-articleLarge.jpg", "xlargeheight": "899", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 899}, {"url": "images/2016/03/29/business/29dbsorkin-sub/29dbsorkin-sub-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/03/29/business/29dbsorkin-sub/29dbsorkin-sub-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "1095", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "ValueAct deserves credit \u2014 or blame \u2014 for virtually everything that happened to Valeant Pharmaceuticals over nearly the last decade.", "pub_date": "2016-03-29T00:00:00Z", "news_desk": "Business", "headline": {"kicker": "DealBook Column", "print_headline": "Another Firm Pays a Price for Its Supporting Role at Valeant", "main": "ValueAct Pays a Price for Its Supporting Role at Valeant", "content_kicker": "DealBook"}, "print_page": "1", "snippet": "ValueAct deserves credit \u2014 or blame \u2014 for virtually everything that happened to Valeant Pharmaceuticals over nearly the last decade.", "_id": "56f9d31538f0d874a87cb0c6", "slideshow_credits": null, "abstract": "Andrew Ross Sorkin DealBook column examines role of activist investment firm ValueAct, founded by Jeffrey Ubben, in designing executive compensation policies at Valeant Pharmaceuticals; critics suggest ValueAct's support of J Michael Pearson as Valeant's chief executive laid path for aggressive accounting practices that, along with decision to significantly increase drug prices, have sparked federal investigations. "}